Rilzabrutinib

7 trials 4 recruiting Orphan designation

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

4 Recruiting

3 Completed trials

2 Sponsors

15 Countries

Phase III

Phase II

Phase I/II

Phase III: 4 Phase II: 2 Phase I/II: 1

Indications tested

Autoimmune haemolytic anaemia 2 Sickle cell disease 1 Graves´ disease 1

Sponsors using this IMP

Sanofi-Aventis Recherche & Developpement 5 Principia Biopharma Inc. 2

All trials

7 total

A study to test how well an oral medication called rilzabrutinib works and how safe it is for adults with immune thrombocytopenia (ITP) who … Recruiting

2025-522070-36-00 Phase III 8 countries Sanofi-Aventis Recherche & Developpement
The efficacy and safety of rilzabrutinib in participants aged 10 to 65 years with sickle-cell disease Recruiting

2024-518645-17-00 Phase III 7 countries Sanofi-Aventis Recherche & Developpement
A study to investigate the efficacy and safety of rilzabrutinib in adult participants with Graves’ disease Recruiting

2025-521023-75-00 Phase II 3 countries Sanofi-Aventis Recherche & Developpement
A study to investigate the efficacy, safety, and pharmacokinetics of oral rilzabrutinib compared with placebo in participants 18 years of ag… Recruiting

2024-517972-39-00 Phase III 11 countries Sanofi-Aventis Recherche & Developpement
Efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia Ended

2023-509441-13-00 Phase II 3 countries Sanofi-Aventis Recherche & Developpement
A Clinical Trial to Test the Safety, Effect, and Activity of Rilzabrutinib (PRN1008) in Adult and Adolescent Patients with Persistent or Chr… Ended

2023-509401-71-00 Phase III 7 countries Principia Biopharma Inc.
A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP) Ended

2023-509397-39-00 Phase I/II 3 countries Principia Biopharma Inc.

Showing 1–7 of 7 trials

← All drugs A–Z